JENNIFER LINGERFELT: Open Payments
NPI 1043440167 · ANDERSON, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,114 in 69 payments from 15 companies in 2025. Trend: 2023 $19 · 2024 $376 · 2025 $1,114
Food & beverage: $1,114
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 21 | $231 |
| Novo Nordisk Inc | 13 | $191 |
| AstraZeneca Pharmaceuticals LP | 5 | $173 |
| Lilly USA, LLC | 11 | $124 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $97 |
| Vanda Pharmaceuticals Inc. | 2 | $43 |
| PFIZER INC. | 2 | $38 |
| Xeris Pharmaceuticals, Inc. | 2 | $36 |
| Exact Sciences Corporation | 2 | $33 |
| Edwards Lifesciences Corporation | 1 | $31 |
Products named: VRAYLAR, BREZTRI, MOUNJARO, CAPLYTA, Ozempic, FARXIGA, Wegovy, Rybelsus.
Industry payments across SC — which companies pay providers there.
